![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-demecolcine | decreases expression | ISO | RGD:1323814 | 6480464 | Demecolcine results in decreased expression of DYRK2 mRNA | CTD | PMID:23649840 | 17beta-estradiol | multiple interactions | ISO | RGD:1323814 | 6480464 | [Progesterone co-treated with Estradiol] results in decreased expression of DYRK2 mRNA | CTD | PMID:17404688 | 17beta-estradiol | decreases expression | ISO | RGD:1323814 | 6480464 | Estradiol results in decreased expression of DYRK2 mRNA | CTD | PMID:26865669, PMID:28711546 | 2,2',4,4',5,5'-hexachlorobiphenyl | multiple interactions | ISO | RGD:1622296 | 6480464 | [2 more ... | CTD | PMID:25510870 | 2,2',5,5'-tetrachlorobiphenyl | multiple interactions | ISO | RGD:1622296 | 6480464 | [2 more ... | CTD | PMID:25510870 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of DYRK2 mRNA | CTD | PMID:22298810 | 2,4-diaminotoluene | decreases expression | ISO | RGD:1622296 | 6480464 | 2, 4-diaminotoluene results in decreased expression of DYRK2 mRNA | CTD | PMID:20713471 | 2-methylcholine | affects expression | ISO | RGD:1323814 | 6480464 | beta-methylcholine affects the expression of DYRK2 mRNA | CTD | PMID:21179406 | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | RGD:1622296 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of DYRK2 mRNA | CTD | PMID:26251327 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1323814 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA | CTD | PMID:28628672 | 3-methylcholanthrene | decreases expression | ISO | RGD:1622296 | 6480464 | Methylcholanthrene results in decreased expression of DYRK2 mRNA | CTD | PMID:20713471 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | RGD:1323814 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA | CTD | PMID:28628672 | 4-nitrobenzaldehyde | multiple interactions | ISO | RGD:1323814 | 6480464 | [Curcumin binds to 4-nitrobenzaldehyde] which results in decreased activity of DYRK2 protein | CTD | PMID:33617879 | 5-iodotubercidin | decreases activity | ISO | RGD:1323814 | 6480464 | 5-iodotubercidin results in decreased activity of DYRK2 protein | CTD | PMID:26953159 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of DYRK2 mRNA | CTD | PMID:24780913 | all-trans-retinoic acid | increases expression | ISO | RGD:1323814 | 6480464 | Tretinoin results in increased expression of DYRK2 mRNA | CTD | PMID:23830798 | amphetamine | decreases expression | EXP | | 6480464 | Amphetamine results in decreased expression of DYRK2 mRNA | CTD | PMID:30779732 | antirheumatic drug | increases expression | ISO | RGD:1323814 | 6480464 | Antirheumatic Agents results in increased expression of DYRK2 mRNA | CTD | PMID:24449571 | aristolochic acid | decreases expression | ISO | RGD:1323814 | 6480464 | aristolochic acid I results in decreased expression of DYRK2 mRNA | CTD | PMID:33212167 | arsenite(3-) | multiple interactions | ISO | RGD:1323814 | 6480464 | arsenite inhibits the reaction [G3BP1 protein binds to DYRK2 mRNA] | CTD | PMID:32406909 | arsenous acid | increases expression | ISO | RGD:1323814 | 6480464 | Arsenic Trioxide results in increased expression of DYRK2 mRNA | CTD | PMID:20458559 | benzo[a]pyrene | increases expression | ISO | RGD:1622296 | 6480464 | Benzo(a)pyrene results in increased expression of DYRK2 mRNA | CTD | PMID:22228805 | benzo[a]pyrene | affects methylation | ISO | RGD:1323814 | 6480464 | Benzo(a)pyrene affects the methylation of DYRK2 exon, Benzo(a)pyrene affects the methylation of DYRK2 promoter | CTD | PMID:27901495, PMID:30157460 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1323814 | 6480464 | 7 more ... | CTD | PMID:20382639, PMID:26238291 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of DYRK2 mRNA | CTD | PMID:25181051 | bisphenol A | decreases methylation | ISO | RGD:1622296 | 6480464 | bisphenol A results in decreased methylation of DYRK2 promoter | CTD | PMID:27312807 | bisphenol A | decreases expression | ISO | RGD:1323814 | 6480464 | bisphenol A results in decreased expression of DYRK2 mRNA | CTD | PMID:28711546 | C60 fullerene | increases expression | EXP | | 6480464 | fullerene C60 results in increased expression of DYRK2 mRNA | CTD | PMID:19167457 | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of DYRK2 mRNA | CTD | PMID:33453195 | carbon nanotube | decreases expression | ISO | RGD:1622296 | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | CGP 52608 | multiple interactions | ISO | RGD:1323814 | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to DYRK2 gene] | CTD | PMID:28238834 | cisplatin | increases expression | ISO | RGD:1323814 | 6480464 | Cisplatin results in increased expression of DYRK2 protein | CTD | PMID:21660965 | cisplatin | multiple interactions | ISO | RGD:1323814 | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of DYRK2 mRNA | CTD | PMID:27392435 | cisplatin | decreases expression | ISO | RGD:1323814 | 6480464 | Cisplatin results in decreased expression of DYRK2 mRNA | CTD | PMID:27392435 | copper atom | increases expression | EXP | | 6480464 | Copper results in increased expression of DYRK2 mRNA | CTD | PMID:30556269 | copper(0) | increases expression | EXP | | 6480464 | Copper results in increased expression of DYRK2 mRNA | CTD | PMID:30556269 | Cuprizon | affects expression | EXP | | 6480464 | Cuprizone affects the expression of DYRK2 mRNA | CTD | PMID:27523638 | Cuprizon | decreases expression | EXP | | 6480464 | Cuprizone results in decreased expression of DYRK2 mRNA | CTD | PMID:26577399 | curcumin | multiple interactions | ISO | RGD:1323814 | 6480464 | [Curcumin binds to 4-nitrobenzaldehyde] which results in decreased activity of DYRK2 protein | CTD | PMID:33617879 | curcumin | decreases activity | ISO | RGD:1323814 | 6480464 | Curcumin results in decreased activity of DYRK2 protein | CTD | PMID:33617879 | DDT | decreases methylation | EXP | | 6480464 | DDT results in decreased methylation of DYRK2 gene | CTD | PMID:31682807 | dexamethasone | multiple interactions | ISO | RGD:1323814 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA | CTD | PMID:28628672 | diarsenic trioxide | increases expression | ISO | RGD:1323814 | 6480464 | Arsenic Trioxide results in increased expression of DYRK2 mRNA | CTD | PMID:20458559 | diazinon | increases methylation | ISO | RGD:1323814 | 6480464 | Diazinon results in increased methylation of DYRK2 gene | CTD | PMID:22964155 | dibutyl phthalate | increases expression | ISO | RGD:1622296 | 6480464 | Dibutyl Phthalate results in increased expression of DYRK2 mRNA | CTD | PMID:21266533 | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of DYRK2 mRNA | CTD | PMID:21266533 | diethylstilbestrol | decreases expression | ISO | RGD:1323814 | 6480464 | Diethylstilbestrol results in decreased expression of DYRK2 mRNA | CTD | PMID:26865669 | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of DYRK2 mRNA | CTD | PMID:29391264 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of DYRK2 mRNA | CTD | PMID:24136188 | folic acid | decreases expression | ISO | RGD:1622296 | 6480464 | Folic Acid results in decreased expression of DYRK2 mRNA | CTD | PMID:25629700 | formaldehyde | decreases expression | ISO | RGD:1323814 | 6480464 | Formaldehyde results in decreased expression of DYRK2 mRNA | CTD | PMID:20655997, PMID:23649840 | fulvestrant | increases expression | ISO | RGD:1323814 | 6480464 | fulvestrant results in increased expression of DYRK2 mRNA | CTD | PMID:26865669 | genistein | decreases expression | ISO | RGD:1323814 | 6480464 | Genistein results in decreased expression of DYRK2 mRNA | CTD | PMID:26865669 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of DYRK2 mRNA | CTD | PMID:22061828 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of DYRK2 mRNA | CTD | PMID:33387578 | glafenine | decreases expression | EXP | | 6480464 | Glafenine results in decreased expression of DYRK2 mRNA | CTD | PMID:24136188 | hexestrol | decreases expression | ISO | RGD:1323814 | 6480464 | Hexestrol results in decreased expression of DYRK2 mRNA | CTD | PMID:26865669 | indometacin | multiple interactions | ISO | RGD:1323814 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA | CTD | PMID:28628672 | irinotecan | decreases expression | ISO | RGD:1323814 | 6480464 | Irinotecan metabolite results in decreased expression of DYRK2 mRNA, Irinotecan results in decreased expression of DYRK2 mRNA | CTD | PMID:15956246 | irinotecan | affects expression | EXP | | 6480464 | Irinotecan affects the expression of DYRK2 mRNA | CTD | PMID:20097248 | menadione | affects expression | ISO | RGD:1323814 | 6480464 | Vitamin K 3 affects the expression of DYRK2 mRNA | CTD | PMID:20044591 | mestranol | decreases expression | ISO | RGD:1323814 | 6480464 | Mestranol results in decreased expression of DYRK2 mRNA | CTD | PMID:26865669 | methapyrilene | decreases expression | EXP | | 6480464 | Methapyrilene results in decreased expression of DYRK2 mRNA | CTD | PMID:30467583 | methoxyacetic acid | affects expression | EXP | | 6480464 | methoxyacetic acid affects the expression of DYRK2 mRNA | CTD | PMID:20864626 | methyl methanesulfonate | decreases expression | ISO | RGD:1323814 | 6480464 | Methyl Methanesulfonate results in decreased expression of DYRK2 mRNA | CTD | PMID:23649840 | Methylazoxymethanol acetate | increases expression | EXP | | 6480464 | Methylazoxymethanol Acetate results in increased expression of DYRK2 mRNA | CTD | PMID:28349193 | methylmercury chloride | decreases expression | ISO | RGD:1323814 | 6480464 | methylmercuric chloride results in decreased expression of DYRK2 mRNA | CTD | PMID:28001369 | mitoxantrone | affects response to substance | ISO | RGD:1323814 | 6480464 | DYRK2 protein affects the susceptibility to Mitoxantrone | CTD | PMID:16217747 | paracetamol | decreases expression | ISO | RGD:1323814 | 6480464 | Acetaminophen results in decreased expression of DYRK2 mRNA | CTD | PMID:22230336 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of DYRK2 mRNA | CTD | PMID:33387578 | parathion | decreases expression | ISO | RGD:1622296 | 6480464 | Parathion results in decreased expression of DYRK2 mRNA | CTD | PMID:34813904 | PCB138 | multiple interactions | ISO | RGD:1622296 | 6480464 | [2 more ... | CTD | PMID:25510870 | phenobarbital | affects expression | ISO | RGD:1323814 | 6480464 | Phenobarbital affects the expression of DYRK2 mRNA | CTD | PMID:19159669 | pirinixic acid | multiple interactions | ISO | RGD:1622296 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of DYRK2 mRNA | CTD | PMID:19710929 | progesterone | multiple interactions | ISO | RGD:1323814 | 6480464 | [Progesterone co-treated with Estradiol] results in decreased expression of DYRK2 mRNA | CTD | PMID:17404688 | propiconazole | decreases expression | ISO | RGD:1622296 | 6480464 | propiconazole results in decreased expression of DYRK2 mRNA | CTD | PMID:21278054 | pyrazinecarboxamide | decreases expression | EXP | | 6480464 | Pyrazinamide results in decreased expression of DYRK2 mRNA | CTD | PMID:22431067 | raloxifene | increases expression | ISO | RGD:1323814 | 6480464 | Raloxifene Hydrochloride results in increased expression of DYRK2 mRNA | CTD | PMID:26865669 | resveratrol | multiple interactions | ISO | RGD:1323814 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of DYRK2 mRNA, [Plant Extracts co-treated with Resveratrol] results in increased expression of DYRK2 mRNA | CTD | PMID:23557933 | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of DYRK2 mRNA | CTD | PMID:28374803 | Soman | increases expression | EXP | | 6480464 | Soman results in increased expression of DYRK2 mRNA | CTD | PMID:19281266 | tetrachloromethane | decreases expression | ISO | RGD:1622296 | 6480464 | Carbon Tetrachloride results in decreased expression of DYRK2 mRNA | CTD | PMID:31919559 | troglitazone | decreases expression | ISO | RGD:1622296 | 6480464 | troglitazone results in decreased expression of DYRK2 mRNA | CTD | PMID:28973697 | urethane | increases expression | ISO | RGD:1323814 | 6480464 | Urethane results in increased expression of DYRK2 mRNA | CTD | PMID:28818685 | valproic acid | affects expression | ISO | RGD:1323814 | 6480464 | Valproic Acid affects the expression of DYRK2 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1323814 | 6480464 | Valproic Acid results in decreased expression of DYRK2 mRNA | CTD | PMID:23179753, PMID:27188386 | valsartan | multiple interactions | ISO | RGD:1323814 | 6480464 | Valsartan inhibits the reaction [AGT protein results in increased expression of DYRK2 mRNA] | CTD | PMID:19225232 | vinclozolin | affects expression | EXP | | 6480464 | vinclozolin affects the expression of DYRK2 mRNA | CTD | PMID:19015723 | |